Lantern Pharma Inc. announced that it will present positive data highlighting the anti-tumor potency of its drug candidate LP-284 for non-Hodgkin's lymphoma (NHL) at the Society of Hematologic Oncology (SOHO) Eleventh Annual Meeting occurring on Sept. 6 - 9, 2023, at the George R. Brown Convention Center in Houston, Texas. LP-284 is a small molecule with a synthetically lethal mechanism of action that preferentially damages cancer cells.

Lantern is developing LP-284 for the treatment of relapsed or refractory NHL, including Mantle Cell Lymphoma and Double Hit Lymphomas. Lantern expects to initiate Phase 1 clinical trials for LP-284 during Fourth Quarter of 2023. Lantern's LP-284 program has been accelerated and de-risked using AI insights and biological modeling powered by RADR®?.

Lantern has been able to advance LP-284 from initial RADR®? insights regarding anti-cancer activity and potential mechanisms of action in hematological cancers, to selection of specific subtypes of lymphomas with superior response, to late-stage IND enabling studies, and initial design of first in human clinical trials in less than two years.